188 related articles for article (PubMed ID: 15821106)
1. Effect of inactivating mutations on phosphorylation and internalization of the human VPAC2 receptor.
Langer I; Langlet C; Robberecht P
J Mol Endocrinol; 2005 Apr; 34(2):405-14. PubMed ID: 15821106
[TBL] [Abstract][Full Text] [Related]
2. Asn229 in the third helix of VPAC1 receptor is essential for receptor activation but not for receptor phosphorylation and internalization: comparison with Asn216 in VPAC2 receptor.
Nachtergael I; Gaspard N; Langlet C; Robberecht P; Langer I
Cell Signal; 2006 Dec; 18(12):2121-30. PubMed ID: 16650965
[TBL] [Abstract][Full Text] [Related]
3. Mutations in the carboxy-terminus of the third intracellular loop of the human recombinant VPAC1 receptor impair VIP-stimulated [Ca2+]i increase but not adenylate cyclase stimulation.
Langer I; Robberecht P
Cell Signal; 2005 Jan; 17(1):17-24. PubMed ID: 15451021
[TBL] [Abstract][Full Text] [Related]
4. Serine 447 in the carboxyl tail of human VPAC1 receptor is crucial for agonist-induced desensitization but not internalization of the receptor.
Marie JC; Rouyer-Fessard C; Couvineau A; Nicole P; Devaud H; El Benna J; Laburthe M
Mol Pharmacol; 2003 Dec; 64(6):1565-74. PubMed ID: 14645688
[TBL] [Abstract][Full Text] [Related]
5. A small sequence in the third intracellular loop of the VPAC(1) receptor is responsible for its efficient coupling to the calcium effector.
Langer I; Vertongen P; Perret J; Waelbroeck M; Robberecht P
Mol Endocrinol; 2002 May; 16(5):1089-96. PubMed ID: 11981043
[TBL] [Abstract][Full Text] [Related]
6. Vasoactive intestinal peptide (VIP) stimulates [Ca2+]i and cyclic AMPin CHO cells expressing Galpha16.
Langer I; Perret J; Vertongen P; Waelbroeck M; Robberecht P
Cell Calcium; 2001 Oct; 30(4):229-34. PubMed ID: 11587546
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a novel VPAC(1) selective agonist and identification of the receptor domains implicated in the carboxyl-terminal peptide recognition.
Van Rampelbergh J; Juarranz MG; Perret J; Bondue A; Solano RM; Delporte C; De Neef P; Robberecht P; Waelbroeck M
Br J Pharmacol; 2000 Jun; 130(4):819-26. PubMed ID: 10864888
[TBL] [Abstract][Full Text] [Related]
8. Mutational analysis of the human vasoactive intestinal peptide receptor subtype VPAC(2): role of basic residues in the second transmembrane helix.
Vertongen P; Solano RM; Perret J; Langer I; Robberecht P; Waelbroeck M
Br J Pharmacol; 2001 Aug; 133(8):1249-54. PubMed ID: 11498510
[TBL] [Abstract][Full Text] [Related]
9. Ac His1 [D-Phe2, K15, R16, L27] VIP (3-7)/GRF (8-27)--a VPAC1 receptor antagonist--is an inverse agonist on two constitutively active truncated VPAC1 receptors.
Vertongen P; Langlet C; Langer I; Gaspard N; Robberecht P
Peptides; 2004 Nov; 25(11):1943-9. PubMed ID: 15501526
[TBL] [Abstract][Full Text] [Related]
10. Evidence for a direct interaction between the Thr11 residue of vasoactive intestinal polypeptide and Tyr184 located in the first extracellular loop of the VPAC2 receptor.
Nachtergael I; Vertongen P; Langer I; Perret J; Robberecht P; Waelbroeck M
Biochem J; 2003 Mar; 370(Pt 3):1003-9. PubMed ID: 12475394
[TBL] [Abstract][Full Text] [Related]
11. Characterization of novel splice variants of the PAC1 receptor in human neuroblastoma cells: consequences for signaling by VIP and PACAP.
Lutz EM; Ronaldson E; Shaw P; Johnson MS; Holland PJ; Mitchell R
Mol Cell Neurosci; 2006 Feb; 31(2):193-209. PubMed ID: 16226889
[TBL] [Abstract][Full Text] [Related]
12. Two tyrosine residues in the first transmembrane helix of the human vasoactive intestinal peptide receptors play a role in supporting the active conformation.
Perret J; Vertongen P; Solano RM; Langer I; Cnudde J; Robberecht P; Waelbroeck M
Br J Pharmacol; 2002 Aug; 136(7):1042-8. PubMed ID: 12145104
[TBL] [Abstract][Full Text] [Related]
13. Elucidation of the vasoactive intestinal peptide pharmacophore for VPAC(2) receptors in human and rat and comparison to the pharmacophore for VPAC(1) receptors.
Igarashi H; Ito T; Pradhan TK; Mantey SA; Hou W; Coy DH; Jensen RT
J Pharmacol Exp Ther; 2002 Nov; 303(2):445-60. PubMed ID: 12388623
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy of VIP and analogs on activation and internalization of the recombinant VPAC2 receptor expressed in CHO cells.
Langlet C; Gaspard N; Nachtergael I; Robberecht P; Langer I
Peptides; 2004 Dec; 25(12):2079-86. PubMed ID: 15572195
[TBL] [Abstract][Full Text] [Related]
15. The human vasoactive intestinal Peptide/Pituitary adenylate cyclase activating peptide receptor 1 (VPAC1): constitutive activation by mutations at threonine 343.
Gaudin P; Couvineau A; Rouyer-Fessard C; Maoret JJ; Laburthe M
Biochem Biophys Res Commun; 1999 Jan; 254(1):15-20. PubMed ID: 9920725
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms involved in vasoactive intestinal peptide receptor activation and regulation: current knowledge, similarities to and differences from the A family of G-protein-coupled receptors.
Langer I; Robberecht P
Biochem Soc Trans; 2007 Aug; 35(Pt 4):724-8. PubMed ID: 17635134
[TBL] [Abstract][Full Text] [Related]
17. Cross-chimeric analysis of selectivity of secretin and VPAC(1) receptor activation.
Park CG; Ganguli SC; Pinon DI; Hadac EM; Miller LJ
J Pharmacol Exp Ther; 2000 Nov; 295(2):682-8. PubMed ID: 11046106
[TBL] [Abstract][Full Text] [Related]
18. Tryptophan 67 in the human VPAC(1) receptor: crucial role for VIP binding.
Nicole P; Maoret JJ; Couvineau A; Momany FA; Laburthe M
Biochem Biophys Res Commun; 2000 Sep; 276(2):654-9. PubMed ID: 11027527
[TBL] [Abstract][Full Text] [Related]
19. Aspartate 196 in the first extracellular loop of the human VIP1 receptor is essential for VIP binding and VIP-stimulated cAMP production.
Du K; Nicole P; Couvineau A; Laburthe M
Biochem Biophys Res Commun; 1997 Jan; 230(2):289-92. PubMed ID: 9016768
[TBL] [Abstract][Full Text] [Related]
20. Site-directed mutagenesis of human vasoactive intestinal peptide receptor subtypes VIP1 and VIP2: evidence for difference in the structure-function relationship.
Nicole P; Du K; Couvineau A; Laburthe M
J Pharmacol Exp Ther; 1998 Feb; 284(2):744-50. PubMed ID: 9454823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
